Normally I would salivate over a workshop titled “Let Me Be Clear: Science Journalism in the Age of the Genome and Twitter“. OK, yes, I admit to being a nerd about both science and journalism. When I received an e-mail about this event, I clicked through right away to learn more. As I read phrases
[continue reading...]
Reaccreditation can be an exacting process. Has your company/institution gone through the process recently? Do you have advice to share to smooth the way for others? Please leave a comment below with your advice to earn the CME community’s undying gratitude.
The irrepressible ProPublica has been at it again, cross-checking, compiling and organizing the flow of cash from drug companies to doctors. Among the 12 drug companies which have revealed data (most of whom have been forced to do in the context of legal settlements) we are now up to $760 million in payments from 2009
[continue reading...]
We’ve been beefing up our Carlat CME Institute website. Our latest feature is the “CME Rogue’s Gallery” (you can view it on the bome page) in which we keep a running list of the most blatantly promotional CME programs that cross our path. Currently we are spotlighting a program funded by Mylan Pharmaceuticals to increase
[continue reading...]
Have you run across an accredited CME course that is so blatantly promotional that you find yourself getting queasy? Please tell us about it. We’ll investigate it, and if it meets our criteria for promotional CME, we may very well post it on our official CME Rogue’s Gallery page—and we will acknowledge you if you
[continue reading...]
The June 2010 issue of “Counseling Points” was body-snatched by Janssen Pharmaceuticals, and became an ACCME accredited advertisement for Risperdal Consta and Invega Sustenna. See the Carlat Psychiatry Blog exposè here.
Stephen Stahl’s company NEI (Neuroscience Institute) produces plenty of good psychiatric education, much of it funded by subscription fees paid by doctors. But the more lucrative part of their business is churning out industry-supported CME. This is an activity funded by Avanir, maker of Nuedexta. Based on a “real patient case,” the course describes a
[continue reading...]
MAOIs are tricky to prescribe. Are they really worth the risks of drug and food interactions? Are they actually more effective than SSRIs for atypical depression? These are tough questions to answer. Do you trust two MECCs paid by the maker of EMSAM to give you accurate answers? God help your patients if you do.
[continue reading...]
